Jaguar Health (NASDAQ:JAGX) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Jaguar Health (NASDAQ:JAGX) in a research note issued to investors on Wednesday. The brokerage issued a sell rating on the biotechnology company’s stock.

Jaguar Health Price Performance

Jaguar Health stock opened at $0.26 on Wednesday. The company has a debt-to-equity ratio of 6.33, a current ratio of 2.00 and a quick ratio of 1.34. The company’s 50 day simple moving average is $0.13 and its 200-day simple moving average is $0.17. Jaguar Health has a 1 year low of $0.05 and a 1 year high of $1.22.

Jaguar Health Company Profile

Jaguar Health, Inc, a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.